Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also dev… Read more
Protalix Biotherapeutics Inc (PLX) - Total Assets
Latest total assets as of September 2025: $82.26 Million USD
Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) holds total assets worth $82.26 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Protalix Biotherapeutics Inc - Total Assets Trend (1996–2024)
This chart illustrates how Protalix Biotherapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Protalix Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Protalix Biotherapeutics Inc's total assets of $82.26 Million consist of 81.8% current assets and 18.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $19.76 Million | 26.9% |
| Accounts Receivable | $2.91 Million | 4.0% |
| Inventory | $21.24 Million | 28.9% |
| Property, Plant & Equipment | $10.02 Million | 13.7% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Protalix Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Protalix Biotherapeutics Inc's current assets represent 81.8% of total assets in 2024, a decrease from 99.9% in 1996.
- Cash Position: Cash and equivalents constituted 26.9% of total assets in 2024, up from 10.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 28.9% of total assets.
Protalix Biotherapeutics Inc Competitors by Total Assets
Key competitors of Protalix Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Protalix Biotherapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Protalix Biotherapeutics Inc generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Protalix Biotherapeutics Inc generates $ 3.99 in net profit.
Protalix Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 1.98 | 0.64 |
| Quick Ratio | 2.06 | 1.27 | 0.49 |
| Cash Ratio | 0.62 | 1.13 | 0.00 |
| Working Capital | $44.56 Million | $ 23.63 Million | $ -30.75 Million |
Protalix Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Protalix Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.26 |
| Latest Market Cap to Assets Ratio | 2.17 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | $73.42 Million |
| Market Capitalization | $158.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Protalix Biotherapeutics Inc's assets at a significant premium ( 2.17x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Protalix Biotherapeutics Inc's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Protalix Biotherapeutics Inc (1996–2024)
The table below shows the annual total assets of Protalix Biotherapeutics Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $73.42 Million | -13.05% |
| 2023-12-31 | $84.43 Million | +51.35% |
| 2022-12-31 | $55.79 Million | -24.27% |
| 2021-12-31 | $73.67 Million | +8.44% |
| 2020-12-31 | $67.93 Million | +49.66% |
| 2019-12-31 | $45.39 Million | -25.75% |
| 2018-12-31 | $61.13 Million | -15.35% |
| 2017-12-31 | $72.21 Million | -12.20% |
| 2016-12-31 | $82.25 Million | -15.43% |
| 2015-12-31 | $97.25 Million | +23.94% |
| 2014-12-31 | $78.47 Million | -30.76% |
| 2013-12-31 | $113.33 Million | +43.96% |
| 2012-12-31 | $78.73 Million | +51.97% |
| 2011-12-31 | $51.80 Million | -19.97% |
| 2010-12-31 | $64.73 Million | -34.40% |
| 2009-12-31 | $98.67 Million | +94.19% |
| 2008-12-31 | $50.81 Million | -25.43% |
| 2007-12-31 | $68.14 Million | +152.47% |
| 2006-12-31 | $26.99 Million | +2633.35% |
| 2005-12-31 | $987.36K | +74.50% |
| 2004-12-31 | $565.84K | -22.94% |
| 2003-12-31 | $734.25K | -16.11% |
| 2002-12-31 | $875.22K | -14.46% |
| 2001-12-31 | $1.02 Million | -46.27% |
| 2000-12-31 | $1.90 Million | -7.01% |
| 1999-12-31 | $2.05 Million | -57.09% |
| 1998-12-31 | $4.77 Million | -36.08% |
| 1997-12-31 | $7.47 Million | +1.73% |
| 1996-12-31 | $7.34 Million | -- |